Using tissue samples from primary renal tumors and matching resected or biopsied metastatic deposits, researchers reported new insights into determining which patients may benefit most from such mTOR inhibitors as temsirolimus (Torisel) and everolimus (Afinitor).
Washington-The mTOR/p70S6 kinase pathway is an important element of carcinogenesis in renal cell carcinoma, and its inhibition is often helpful in treating patients with advanced disease. But clinicians find that not all patients respond to mTOR inhibitors, raising the question of exactly which types of tumors are best treated with those agents.
Using tissue samples from primary renal tumors and matching resected or biopsied metastatic deposits, first author Alexander Kutikov, MD, and colleagues reported new insights into determining which patients may benefit most from such mTOR inhibitors as temsirolimus (Torisel) and everolimus (Afinitor).
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.